Cambridge Heart and Lung Research Institute receives major funding boost

The new Cambridge Heart and Lung Research Institute (HLRI) (artist's impression)

Chris Skidmore, Minister for Universities, Science, Research and Innovation, has announced a £30 million award to the University of Cambridge to support the new Cambridge Heart and Lung Research Institute (HLRI).

The Institute will draw together the highest concentration of heart and lung researchers from academia, healthcare and industry in Europe. It has set an ambitious five year target to demonstrate proof-of-concept for at least ten new drugs or diagnostic approaches in heart and lung diseases.

The HLRI will be situated next to Royal Papworth Hospital, which was officially opened by HM the Queen yesterday, and forms part of the Cambridge Biomedical Campus, the centrepiece of the largest biotech cluster outside the United States. It will be home to over 380 scientists and state-of-the-art laboratories in genomics, population sciences, research into cellular mechanisms of disease and translational science. It will also include a special ten bed facility where the first-in-patient studies of new treatments can be conducted.

“This is an incredibly exciting project bringing together world-renowned expertise in cardiovascular and respiratory science at Cambridge University and clinical excellence at Royal Papworth Hospital,” says Professor Nick Morrell from the University of Cambridge, Interim Director of the institute and a non-Executive Director of Royal Papworth Hospital.

“Heart and lung diseases affect many millions of people of people worldwide and the numbers are growing. Institutes such as ours, focussed on these big health challenges, are urgently needed. The discoveries made by our researchers will deliver major benefits to the public through improvements in public health, new approaches to diagnosing and treating disease, and new medicines.”

Professor John Wallwork, Chairman of Royal Papworth Hospital, said: “The Heart and Lung Research Institute will mean new treatments will be created, tested and delivered to tackle the biggest causes of premature death in the world all on one site. This will be a huge step forward and demonstrates one of the reasons Royal Papworth Hospital moved to the Cambridge Biomedical Campus – to collaborate with the best researchers in the world to help to save lives. The importance of this building cannot be underestimated and I can’t wait to see how it will transform healthcare in the years to come.”

The award is one of 11 announced from flagship capital investment scheme the UK Research Partnership Investment Fund, totalling over £670m of new investment into UK research and innovation. It complements £10 million of funding committed to the institute by the British Heart Foundation (BHF). Further funding will be provided by the University and Royal Papworth Hospital, and the Wolfson Foundation.

Read the full story

Reproduced courtesy of the University of Cambridge


The University of Cambridge is acknowledged as one of the world's leading higher education and research institutions. The University was instrumental in the formation of the Cambridge Network and its Vice- Chancellor, Professor Stephen Toope, is also the President of the Cambridge Network.

University of Cambridge (